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Background: Whilst reports on the use of 1% voriconazole
eye drops in the management of ophthalmic fungal kerati-
tis have been promising, the voriconazole concentrations
achieved in the eye were not sufﬁciently high to treat all
types of fungal keratitis. Higher concentration of voricona-
zole eye drops may be required. We investigated the topical
application of 2% voriconazole solution for the management
of ophthalmic mycoses.
Methods: Voriconazole solution (2%) was prepared by
reconstituting intravenous Vfend® with sterile water pre-
served with 0.01% benzalkonium chloride. In a prospective
open label study, non-keratitis patients scheduled for elec-
tive anterior segment eye surgery were recruited to receive
2% voriconazole eye drops hourly, commencing 4 hours
before surgery. Aqueous humour samples were removed
during surgery and analysed by high-performance liquid
chromatography. 2% voriconazole eye drops were concur-
rently stored and monitored for stability.
Results: Fourteen patients participated in the study.
Eight samples were analysed (six samples were insufﬁcient
for analysis). The mean (± standard deviation) voriconazole
concentration was 1.51± 1.00g/mL, and the mean sam-
pling time after last-dose was 1.39 h. No side effects were
reported by patients. The eye drops demonstrated excel-
lent physical and chemical stability at refrigerated and room
temperatures for at least 4 months.
Conclusion: This is the ﬁrst study to report on the topi-
cal application of 2% voriconazole eye drops. The eye drops
appear to be safe, and the concentration of voriconazole
achieved is adequate to treat most common fungal kerati-
tis, and is similar to that reported in literature with the
1% solution administered with the same dosing frequency.
This suggests that the penetration of voriconazole into the
aqueous humour may not be concentration driven, at least
through the intact infection-free cornea.
doi:10.1016/j.ijid.2008.05.764
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Effect of Dodonaea viscosa var. angustifolia on Candida
proteinase production and oral epithelial adherence from
HIV+ and HIV− patients
M. Patel
University of the Witwatersrand and National Health
Laboratory Services, Clinical Microbiology and Infectious
Diseases, Johannesburg, South Africa
Candida albicans isolated from HIV+ patients are known
to be more virulent than from HIV− patients. Critical steps
in oral Candidiasis pathogenisis is oral epithelial cells adher-
ence and proteinase production. The leaves of an indigenous
South African plant Dodonaea viscosa var. angustifolia are
used as a traditional remedy for treating Candidiasis. This
study investigated the effect of a crude extract of this plant
on C. albicans adherence and proteinase production which
were isolated from HIV+ and HIV− patients. Twenty isolates
from HIV+ and 20 from HIV− patients were used in the study.
Proteinase assay (P) and adherence test (A) was done on iso-
lates treated with plant extract (p) and water as a control
(c). For proteinase assay (mg/ml), quantitative spectropho-
tometric analysis was performed. For the adherence test,
Candida cells were treated with plant extract or water and
mixed with freshly isolated oral epithelial cells. The epithe-
lial cells were harvested, washed, slides were prepared
and stained. Adherent Candida cells per 100 epithelial cells
were measured for each test. In proteinase assay, results
were analysed using two-way ANOVA. In adherence test,
results were compared using t-test and the results of iso-
lates from HIV+ and HIV− patients were compared using
two-way ANOVA. Plant extract reduced the adherence of
Candida/100 epithelial cells (HIV+: Ac 316, Ap 203; HIV−: Ac
397, Ap 258) signiﬁcantly in both isolates (p < 0.001). How-
ever, there was no signiﬁcant difference between proteinase
production in isolates from HIV+ (Pp:2.0 and Pc:1.87mg/ml,
p < 0.05) and HIV− patients (Pp and Pc: 1.9mg/ml, p > 0.05).
In adherence test and proteinase assay, there was no dif-
ference in the results of the isolates from HIV+ and HIV−
patients. D. viscosa has ability to signiﬁcantly reduce Can-
dida adhesion to oral epithelial cells.
doi:10.1016/j.ijid.2008.05.765
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Streptomyces species
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Opportunistic fungal infection is common in immunocom-
promised and immunosuppressed patients. Despite advances
in antifungal therapies, many problems remain to be solved
for most antifungal drugs available, for example, the use of
amphotericin B, also known as ‘‘gold standard’’, is limited
because of its infusion-related reactions and nephrotoxic-
ity. Another major problem in the clinical management of
patients with fungal infections is the development of drug
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resistance as exempliﬁed by ﬂuconazole and echinocandins-
resistant Candida spp. This situation highlights the need
for advent of safe, novel and effective antifungal com-
pounds. The objective of this study was to determine
whether secondary metabolites produced by a species of
Streptomyces was able to exert antifungal effects against
seven and ﬁve medically important yeast Candida spp. and
molds Aspergilllus spp. respectively. NCCLS M27A and M38A
methods for MIC determination were followed stringently
in this screening procedure. Our initial work found all of
these fungi were susceptible to the crude fermentative
acetone extract (MIC ≤0.625mg/ml for Candida spp. and
≤2.5mg/ml for Aspergillus spp.). Five ﬂuconazole-resistant
clinical strains were also sensitive to it, with MIC val-
ues ≤0.312mg/ml. In addition, it also totally inhibited C.
albicans ATCC 14053 hyphae growth at 0.5mg/ml. These
promising results showed that potential antifungal com-
pounds from secondary metabolites were produced by this
species of Streptomyces. This work will be further tested
with fractionated extracts and the mechanism of action of
potential bioactive compounds will be elucidated.
doi:10.1016/j.ijid.2008.05.766
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Objective: To prospectively assess the Asian-Paciﬁc expe-
rience with caspofungin administered as monotherapy or
in combination therapy for initial or salvage treatment of
proven or probable invasive aspergillosis (IA).
Methods: A prospective observational registry was devel-
oped to collect data from patients treated with caspofungin
for a single episode of IA. Information was collected from
patients treated between April 2006 to September 2007.
Clinical efﬁcacy was determined by the local investigator as
favorable (complete or partial response) or unfavorable (sta-
ble disease or treatment failure) at the end of caspofungin
therapy (EOCT).
Results: Forty one patients with proven or probable
IA (EORTC/MSG criteria) were enrolled from 9 sites in 4
countries in the Asian-Paciﬁc region - Australia, Korea,
Singapore, and Taiwan. The most frequent underlying con-
ditions included malignancy (71%), allogenic hematopoietic
stem cell transplantation (HSCT, 30%), solid organ transplan-
tation (SOT, 14%) and autologous HSCT (2%). Neutropenia at
start of caspofungin was evident in 66% of cases. Eighteen
patients (44%) had proven IA and the lung was the most com-
mon infection site (73%). In culture-proven cases, Aspergillus
fumigatus was the most frequent species. The majority of
patients received caspofungin monotherapy (88%), primar-
ily as salvage therapy (97%). Most salvage therapy (77%) of
monotherapy group occurred in patients refractory to prior
antifungals. A favorable response at EOCT was seen in 46%
(19/41). Favorable response rates in signiﬁcant subgroups
were: SOT 67% (4/6); allogenic HSCT 42% (5/12); neutrope-
nia 37% (10/27); malignancy 35% (10/29). Only 1 serious
clinical adverse event (respiratory failure) leading to dis-
continuation of drug was reported (2.4%). An overall survival
rate was 68% (28/41) at EOCT.
Conclusion: In daily clinical practice, an overall favor-
able response rate of 46% was observed in patients from
Asian-Paciﬁc region with proven or probable IA treated with
caspofungin monotherapy or combination therapy which is
consistent with the ﬁndings observed in randomized clinical
trials.
doi:10.1016/j.ijid.2008.05.767
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sions to Mulago Hospital, Kampala
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Introduction: In patients with advanced AIDS, oropharyn-
geal candidiasis (OPC) continues to be a common presenting
illness associated with signiﬁcant morbidity. Resistance to
antimicrobial agents aggravates the implications for morbid-
ity and mortality and health care costs in the hospital and
the community. Studies in the USA have shown a correlation
between in vitro antifungal susceptibility testing with the
clinical outcome. In this study we determine and document
the type species and the antifungal susceptibility patterns of
organisms causing OPC among HIV+ adult medical admissions
to Mulago Hospital, Kampala.
Methods: Fifty (50) isolates were obtained from 57 con-
secutive isolates among immune suppressed patients at
Mulago hospital, Kampala. The isolates were identiﬁed using
germ tube formation in serum, chlamydospore formation
and API20C strips. Antifungal susceptibilities were deter-
mined for Nystatin, ﬂuconazole, ketoconazole, miconazole,
Itraconazole, 5- ﬂucytocine and voriconazole using calori-
metric broth microdilution testing.
Results: Ninety percent (90%) of all isolates were C. albi-
cans species, 58% of which were isolated from hyperplastic
lesions. C. dubliniensis and C. glabrata comprised 6% and 4%
of all isolates respectively. Overall the isolates were sensi-
